8

:: JBC :: Journal of Breast Cancer · Methods: Since Nov. 1998, when docetaxel gained Korean approval in the treatment of breast cancer, Tel: 02—527-5239. Fax: 02—527--057. E-mail:

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

Page 1: :: JBC :: Journal of Breast Cancer · Methods: Since Nov. 1998, when docetaxel gained Korean approval in the treatment of breast cancer, Tel: 02—527-5239. Fax: 02—527--057. E-mail:
Page 2: :: JBC :: Journal of Breast Cancer · Methods: Since Nov. 1998, when docetaxel gained Korean approval in the treatment of breast cancer, Tel: 02—527-5239. Fax: 02—527--057. E-mail:
Page 3: :: JBC :: Journal of Breast Cancer · Methods: Since Nov. 1998, when docetaxel gained Korean approval in the treatment of breast cancer, Tel: 02—527-5239. Fax: 02—527--057. E-mail:
Page 4: :: JBC :: Journal of Breast Cancer · Methods: Since Nov. 1998, when docetaxel gained Korean approval in the treatment of breast cancer, Tel: 02—527-5239. Fax: 02—527--057. E-mail:
Page 5: :: JBC :: Journal of Breast Cancer · Methods: Since Nov. 1998, when docetaxel gained Korean approval in the treatment of breast cancer, Tel: 02—527-5239. Fax: 02—527--057. E-mail:
Page 6: :: JBC :: Journal of Breast Cancer · Methods: Since Nov. 1998, when docetaxel gained Korean approval in the treatment of breast cancer, Tel: 02—527-5239. Fax: 02—527--057. E-mail:
Page 7: :: JBC :: Journal of Breast Cancer · Methods: Since Nov. 1998, when docetaxel gained Korean approval in the treatment of breast cancer, Tel: 02—527-5239. Fax: 02—527--057. E-mail:
Page 8: :: JBC :: Journal of Breast Cancer · Methods: Since Nov. 1998, when docetaxel gained Korean approval in the treatment of breast cancer, Tel: 02—527-5239. Fax: 02—527--057. E-mail: